Wegovy vs Foundayo
Tirzepatide (Mounjaro/Zepbound) is superior to semaglutide (Wegovy) for weight loss in adults with obesity, achieving approximately 6% greater total body weight loss at one year. 1
Weight Loss Efficacy
The most recent head-to-head trial (SURMOUNT-5,2025) directly compared maximum tolerated doses of tirzepatide (10-15 mg) versus semaglutide (1.7-2.4 mg) in 751 adults with obesity but without diabetes 1. At 72 weeks:
- Tirzepatide: -20.2% total body weight loss
- Semaglutide: -13.7% total body weight loss
- Difference: 6.5% greater weight loss with tirzepatide (p<0.001)
This finding is consistently supported by multiple 2026 meta-analyses showing tirzepatide's superiority, with mean differences ranging from 4.5-6.1 kg greater absolute weight loss 2.
Achievement of Weight Loss Thresholds
Tirzepatide enables more patients to reach clinically meaningful weight loss targets 1, 3:
- ≥15% weight loss: 56.8% (tirzepatide) vs 40.7% (semaglutide)
- ≥20% weight loss: 39.0% (tirzepatide) vs 22.1% (semaglutide)
- ≥25% weight loss: Significantly higher with tirzepatide
Real-world data from 511 US patients confirms these trial findings, with 12-month weight loss of 16.6% for tirzepatide versus 13.4% for semaglutide 3.
Metabolic Benefits Beyond Weight
Tirzepatide demonstrates superior glycemic control even in patients without diabetes 1, 2:
- HbA1c reduction: 0.33% greater decrease
- Fasting glucose: 10.4 mg/dL greater reduction
- Waist circumference: 5.4 cm greater reduction (-18.4 cm vs -13.0 cm)
Safety Profile Comparison
Gastrointestinal side effects are MORE common with semaglutide than tirzepatide 3:
- Semaglutide: 50.7% reported GI adverse events
- Tirzepatide: 28.5% reported GI adverse events
Both medications share similar serious adverse event profiles, including risks of pancreatitis, gallbladder disease, and contraindication in patients with personal/family history of medullary thyroid cancer 4, 5.
Cardiovascular Considerations
Semaglutide currently has stronger cardiovascular outcome data 4. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (HR 0.80,95% CI 0.72-0.90) in patients with established CVD 4. Tirzepatide has shown cardiovascular non-inferiority but lacks the same depth of cardiovascular benefit evidence 6.
Clinical Algorithm:
- Primary obesity without established CVD: Choose tirzepatide for superior weight loss
- Obesity with established CVD: Consider semaglutide for proven cardiovascular risk reduction
- Prior GLP-1 failure: Switch to tirzepatide (dual GIP/GLP-1 mechanism may overcome resistance)
- GI intolerance concerns: Start with tirzepatide (lower GI side effect rates)
Important Caveats
Both medications require lifelong use—weight regain of 7-12% occurs within one year of discontinuation 4. Prior obesity medication use reduces effectiveness of both agents, though tirzepatide maintains superiority 3.
Oral semaglutide (Rybelsus) at 50 mg daily shows comparable efficacy to subcutaneous semaglutide 2.4 mg (15.1% weight loss) but is not yet FDA-approved for obesity treatment 4, 7.
The evidence unequivocally supports tirzepatide as the more effective obesity medication when cardiovascular disease is not the primary concern.